BNOEF Stock - Bionomics Limited
Unlock GoAI Insights for BNOEF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $23.95M | N/A | N/A | $277,892.5 | N/A |
| Gross Profit | $22.94M | $-992,563 | $-671,419 | N/A | $-1,691,056 |
| Gross Margin | 95.8% | N/A | N/A | 0.0% | N/A |
| Operating Income | $-1,728,231 | $-26,786,676 | $-22,255,712 | $-28,600,707 | $-12,946,664 |
| Net Income | $-565,773 | $-23,193,321 | $-21,646,954 | $-22,936,204 | $-8,646,819 |
| Net Margin | -2.4% | N/A | N/A | -8253.6% | N/A |
| EPS | $-0.23 | $-0.10 | $-0.17 | $-0.13 | $-0.10 |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Visit WebsiteEarnings History & Surprises
BNOEFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 20, 2025 | — | $0.66 | — | — |
Q1 2025 | Feb 14, 2025 | — | $-0.11 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.06 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.00 | — | — |
Q4 2024 | Oct 1, 2024 | — | $-1.48 | — | — |
Q4 2024 | Oct 1, 2024 | — | $-0.33 | — | — |
Q4 2024 | Oct 1, 2024 | — | $-1.18 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.01 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.00 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.37 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.40 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.00 | — | — |
Q4 2022 | Oct 14, 2022 | — | $-0.44 | — | — |
Q4 2022 | Oct 6, 2022 | — | $-0.45 | — | — |
Q1 2022 | Feb 22, 2022 | — | $-1.23 | — | — |
Q3 2021 | Aug 25, 2021 | — | $-1.16 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.00 | — | — |
Q2 2020 | Jun 29, 2020 | — | $-0.11 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-1.04 | — | — |
Q2 2019 | Jun 29, 2019 | — | $0.25 | — | — |
Latest News
Frequently Asked Questions about BNOEF
What is BNOEF's current stock price?
What is the analyst price target for BNOEF?
What sector is Bionomics Limited in?
What is BNOEF's market cap?
Does BNOEF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BNOEF for comparison